Medtronic initiates trial for bluetooth enabled MiniMed 780G AHCL systems
Medtronic announced the enrollment of the first study participants in the company's pivotal trial of its Bluetooth enabled MiniMed 780G advanced hybrid closed loop system, designed to automate the delivery of correction boluses when the user experiences, or is predicted to experience, prolonged high glucose levels based on their sensor readings. The trial will evaluate the safety of the MiniMed 780G system in participants with type 1 diabetes at home, at work, during exercise and other daily activities. The study will enroll up to 350 adult and pediatric participants. Data from the feasibility study demonstrated the safety of the system and its potential to improve overall glycemic control and simplify diabetes management for individuals who forget to administer a bolus of insulin at mealtime, carb count inaccurately or choose to forgo announcing meals. Additionally, hypoglycemia dropped by 27% and hyperglycemia was reduced by 14% with no serious adverse events reported.